LINEAGE CELL THERAPEUTICS INC (LCTX)
Health Care · Cell therapy / regenerative medicine · Nyse Mkt Llc
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships with major pharmaceutical companies.
What LINEAGE CELL THERAPEUTICS INC does
Lineage Cell Therapeutics is a clinical-stage regenerative medicine company developing allogeneic cell therapy product candidates to treat human diseases. The company's primary platform is AlloSCOPE™, which enables the development and manufacture of cell therapies. Lineage collaborates with leading pharmaceutical partners (including F. Hoffmann-La Roche and Genentech) to advance cell therapy development and commercialization.
Themes: ["cell therapy","regenerative medicine","clinical-stage development","allogeneic cell products"]
Fundamentals
- Price$1.29 as of 2026-07-09 close
- Market cap$323M as of 2026-07-10
- 1-year return+21.7% as of 2026-07-09 close
- Net margin-431.2% as of 2026-07-10
- Gross margin+94.1% as of 2026-07-10
- ROE-151.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-37.1% as of 2026-07-10
- Revenue CAGR (3y)-0.3% SEC XBRL
- Beta1.50 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory approval risk for product candidates","Dependence on collaborations and partnerships for milestone payments and revenue","Significant ongoing operating losses and negative cash generation from operations"]
Competitors & peers
- Fate Therapeutics
- Cellular Dynamics
- Sangamo Therapeutics
- CRISPR Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.